Beijing Suncadia Pharmaceuticals Co., Ltd
Clinical trials sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New obesity drug SHR-2906 enters human testing Results expected Dec 2026 (estimated)
- Can a new drug help stroke patients recover better? Results expected Apr 2027 (estimated)
-
Can a new injection shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis trial is testing an investigational drug called SHR-8203, given as an injection, in people with advanced or metastatic solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the safest dose, understand ho…
Phase 1/2 • Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a new drug help stroke patients recover better?
Disease control Not yet recruitingThis trial is testing whether an experimental drug called HRS-4029 can improve outcomes for people who have had an acute ischemic stroke, which happens when a blood clot blocks blood flow to the brain. The study will compare the drug against a placebo in about 340 participants wh…
Phase 2 • Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New heart failure drug SHR-4658 enters first human safety trial
Disease control Not yet recruitingThis early-stage trial tests a single injection of SHR-4658 in 48 healthy volunteers and people with slightly high blood pressure. The main goal is to check safety and how the body processes the drug. If it passes safety checks, it may lead to larger studies for heart failure tre…
Phase 1 • Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC